Insights That Move the GPCR Field Forward

If you’ve felt the pace of GPCR research accelerating—and the signal getting harder to separate from the noise—you’re not alone.This week marks the start of a new era for the Dr. GPCR Ecosystem: sharper programming, deeper expertise, and renewed momentum across everything we publish and build.After a brief pause over the holidays, we’re back in full force—designed to help you make better scientific and strategic decisions, faster.

Dr. Jens Carlsson reveals how predictive modeling is reshaping GPCR drug discovery—bridging computation, chemistry, and pharmacology for real-world impact.

The difference between orthosteric vs. allosteric mechanisms isn’t just academic — an orthosteric antagonist can hijack receptor physiology, while an allosteric modulator works with the system. That choice determines whether you risk over- or under-dosing, miss safety windows, or miss therapeutic breakthroughs.